Kiniksa Pharmaceuticals, Ltd. updated earnings guidance for 2024. For the period, the company expects ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.67 USD | +0.43% | +0.32% | +6.44% |
06-26 | Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday | MT |
06-25 | Kiniksa Pharmaceuticals Signs Deal With Samsung Biologics for Arcalyst Supply | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.44% | 1.32B | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Updates Earnings Guidance for 2024